aclidinium
Respiratory system (R03)Respiratory system (R03) compound in Menarini Asia-Pacific's portfolio. Mechanism: Muscarinic acetylcholine receptor M3 antagonist.
- Mechanism
- Muscarinic acetylcholine receptor M3 antagonist
pharma · Dyslipidemia at High to Very High Cardiovascular Risk · Suspected or confirmed Gram negative infections
Menarini Asia-Pacific
A.Menarini Australia Pty Limited
Menarini Asia-Pacific drug portfolio — 15 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Singapore, SG HQ
720 Employees
TGA registrant Type
Company details
- Status
- Public
- HQ
- Singapore, SG
- Employees
- 720
- Programs
- 2
- Drugs
- 15
- Patents
- 0
Menarini Asia-Pacific pipeline
Portfolio lens on 15 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Menarini Asia-Pacific drug portfolio — 15 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Menarini Asia-Pacific in public FDA and regional records.
-
avanafil
Genito-urinary system and sex hormones (G04)US regulatory status: approved. Molecular target: cGMP-specific 3',5'-cyclic phosphodiesterase.
- Target
- cGMP-specific 3',5'-cyclic phosphodiesterase
- Mechanism
- Phosphodiesterase 5A inhibitor
-
bempedoic acid
Cardiovascular system (C10)US regulatory status: approved. Molecular target: ATP-citrate synthase.
- Target
- ATP-citrate synthase
- Mechanism
- ATP-citrate synthase inhibitor
-
US regulatory status: approved. Molecular target: GABA-A receptor; anion channel.
- Target
- GABA-A receptor; anion channel
- Mechanism
- GABA-A receptor; anion channel positive allosteric modulator
-
febuxostat
Musculo-skeletal system (M04)US regulatory status: approved. Molecular target: Xanthine dehydrogenase/oxidase.
- Target
- Xanthine dehydrogenase/oxidase
- Mechanism
- Xanthine dehydrogenase inhibitor
-
US regulatory status: approved. Mechanism: Supplement.
- Mechanism
- Supplement
-
Development asset linked to Menarini Asia-Pacific in public FDA and regional records.
-
Development asset linked to Menarini Asia-Pacific in public FDA and regional records.
-
meropenem
Antiinfectives for systemic use (J01)US regulatory status: approved. Molecular target: Bacterial penicillin-binding protein.
- Target
- Bacterial penicillin-binding protein
- Mechanism
- Bacterial penicillin-binding protein inhibitor
-
Development asset linked to Menarini Asia-Pacific in public FDA and regional records.
-
Development asset linked to Menarini Asia-Pacific in public FDA and regional records.
-
Development asset linked to Menarini Asia-Pacific in public FDA and regional records.
-
Development asset linked to Menarini Asia-Pacific in public FDA and regional records.
-
Development asset linked to Menarini Asia-Pacific in public FDA and regional records.